Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg QT/PK Study in R/R CD33+ AML
NCT03727750Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Primary endpoint: Change From Baseline in Corrected QT Interval for Heart Rate Using Fridericia's Formula (QTcF). Started Jul 2019; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03727750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727750.